SLFN12

SLFN12 is a cytoplasmic RNase that selectively cleaves tRNALeu(TAA) at its variable loop and acceptor stem, causing ribosome pausing at Leu-TTA codons, global translation inhibition, and apoptosis (PMID:36302897). Small-molecule "velcrin" compounds (DNMDP, anagrelide, nauclefine) act as molecular glues that stabilize a butterfly-shaped PDE3A–SLFN12 heterotetramer; the SLFN12 C-terminal short helix (E552–I558) engages a hydrophobic interface near the PDE3A catalytic pocket, and complex formation increases SLFN12 RNase activity (PMID:34272366, PMID:34707099). Compound-induced complex assembly also triggers dephosphorylation of SLFN12 at S368 and S573, which is required for full RNase activity and cell death (PMID:35104454). Downstream, SLFN12-mediated tRNA depletion activates the GCN2 integrated stress response as an effector of cancer cell killing (PMID:38864850).

1. 2021 High

   Establishing that SLFN12 possesses RNase activity and forms a structurally defined heterotetramer with PDE3A resolved a key question about how velcrin compounds kill cancer cells — not through PDE3A catalytic inhibition but through induced proximity that activates SLFN12 enzymatic function.

   Evidence Cryo-EM and X-ray crystallography of PDE3A–SLFN12 complexes, in vitro RNase assays, and mutagenesis of the SLFN12 C-terminal helix and PDE3A interface residues

   PMID:34272366 PMID:34707099

   Open questions at the time

   • Physiological RNA substrate of SLFN12 RNase was not identified
   • Mechanism by which RNase activity leads to cell death was unclear
   • Whether endogenous (non-drug-induced) signals regulate complex formation was unknown
2. 2022 High

   Identification of tRNALeu(TAA) as the selective physiological substrate of SLFN12 explained how its RNase activity causes translation arrest and apoptosis — cleavage depletes a specific tRNA, stalling ribosomes at cognate codons genome-wide.

   Evidence In vitro tRNA cleavage assays with purified SLFN12, substrate mutagenesis defining cleavage sites, and ribosome profiling showing pausing at Leu-TTA codons in velcrin-treated cells

   PMID:36302897

   Open questions at the time

   • Whether SLFN12 cleaves additional tRNA species under different conditions was not resolved
   • Structural basis for tRNALeu(TAA) selectivity over other tRNAs was not determined
   • How ribosome pausing at specific codons triggers apoptotic commitment remained undefined
3. 2022 High

   Discovery that velcrin-induced complex formation triggers dephosphorylation of SLFN12 at S368 and S573, and that this dephosphorylation is required for RNase activation and cell death, revealed a post-translational regulatory switch controlling SLFN12 enzymatic output.

   Evidence Phosphomimetic and phospho-null mutagenesis, western blot for phosphorylation status, in vitro RNase assay comparing phosphorylated and dephosphorylated SLFN12, and cell viability assays

   PMID:35104454

   Open questions at the time

   • Identity of the phosphatase(s) responsible for S368/S573 dephosphorylation was not established
   • The kinase(s) maintaining basal SLFN12 phosphorylation were not identified
   • Whether dephosphorylation alters SLFN12 substrate specificity or only catalytic rate was not distinguished
4. 2022 Medium

   Linking SLFN12 overexpression to reduced CHK1/CHK2 phosphorylation after DNA damage suggested an additional role for SLFN12 in modulating the DNA damage checkpoint, expanding its functional repertoire beyond tRNA cleavage.

   Evidence Lentiviral SLFN12 overexpression in TNBC cells, western blot for pCHK1/pCHK2 after camptothecin, pharmacological CHK1/CHK2 inhibition rescue experiments

   PMID:35430566

   Open questions at the time

   • No direct biochemical mechanism connecting SLFN12 RNase to checkpoint kinase regulation was established
   • Whether the effect on CHK1/CHK2 is a consequence of translational inhibition rather than a specific signaling function was not distinguished
   • Observations were based on overexpression; endogenous SLFN12 levels were not tested
5. 2024 Medium

   Identification of the GCN2 integrated stress response as a downstream effector of SLFN12-mediated tRNA depletion connected the tRNA cleavage mechanism to a defined stress-sensing pathway that executes cancer cell death.

   Evidence Treatment of patient-derived xenograft GIST models with PDE3A–SLFN12 complex inducer OPB-171775, pathway analysis identifying GCN2 activation

   PMID:38864850

   Open questions at the time

   • Whether GCN2 activation is necessary or merely correlative for cell death was not genetically tested
   • Contribution of other ISR kinases (PERK, HRI, PKR) was not excluded
   • Whether GCN2 senses the cleaved tRNA fragments or the resulting uncharged tRNA pool was not resolved

• The endogenous physiological function of SLFN12 independent of pharmacological molecular glues remains undefined — it is unknown whether natural ligands or conditions promote PDE3A–SLFN12 complex formation, what kinases and phosphatases regulate the S368/S573 switch, and whether SLFN12 has additional RNA substrates or non-catalytic roles.
• No endogenous activating signal for PDE3A–SLFN12 complex formation has been identified
• Kinase/phosphatase network controlling SLFN12 phosphorylation is uncharacterized
• Structural basis for tRNALeu(TAA) selectivity is missing